Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
India’s First Integrated Ayush Wellness Centre to come up in Guwahati, foundation stone laid
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
With India supplying around 60% of the world's vaccine needs and 20-22% of generic exports, the country is dedicated to providing affordable, high-quality drugs and contribute to global accessibility
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
The combination will support clients in getting their end-to-end discovery and development programs delivered.
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
Man Industries (India) Limited has received a new export order of approximately Rs. 1,300 crores.
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
Subscribe To Our Newsletter & Stay Updated
